Literature DB >> 17428871

Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration.

Jean L Mbisa1, Rebekah Barr, James A Thomas, Nick Vandegraaff, Irene J Dorweiler, Evguenia S Svarovskaia, William L Brown, Louis M Mansky, Robert J Gorelick, Reuben S Harris, Alan Engelman, Vinay K Pathak.   

Abstract

Encapsidation of host restriction factor APOBEC3G (A3G) into vif-deficient human immunodeficiency virus type 1 (HIV-1) blocks virus replication at least partly by C-to-U deamination of viral minus-strand DNA, resulting in G-to-A hypermutation. A3G may also inhibit HIV-1 replication by reducing viral DNA synthesis and inducing viral DNA degradation. To gain further insight into the mechanisms of viral inhibition, we examined the metabolism of A3G-exposed viral DNA. We observed that an overall 35-fold decrease in viral infectivity was accompanied by a five- to sevenfold reduction in viral DNA synthesis. Wild-type A3G induced an additional fivefold decrease in the amount of viral DNA that was integrated into the host cell genome and similarly reduced the efficiency with which HIV-1 preintegration complexes (PICs) integrated into a target DNA in vitro. The A3G C-terminal catalytic domain was required for both of these antiviral activities. Southern blotting analysis of PICs showed that A3G reduced the efficiency and specificity of primer tRNA processing and removal, resulting in viral DNA ends that are inefficient substrates for integration and plus-strand DNA transfer. However, the decrease in plus-strand DNA transfer did not account for all of the observed decrease in viral DNA synthesis associated with A3G. These novel observations suggest that HIV-1 cDNA produced in the presence of A3G exhibits defects in primer tRNA processing, plus-strand DNA transfer, and integration.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17428871      PMCID: PMC1933301          DOI: 10.1128/JVI.00272-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Replication of phenotypically mixed human immunodeficiency virus type 1 virions containing catalytically active and catalytically inactive reverse transcriptase.

Authors:  J G Julias; A L Ferris; P L Boyer; S H Hughes
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22.

Authors:  Adam Jarmuz; Ann Chester; Jayne Bayliss; Jane Gisbourne; Ian Dunham; James Scott; Naveenan Navaratnam
Journal:  Genomics       Date:  2002-03       Impact factor: 5.736

3.  Hypermutation of HIV-1 DNA in the absence of the Vif protein.

Authors:  Denise Lecossier; Francine Bouchonnet; François Clavel; Allan J Hance
Journal:  Science       Date:  2003-05-16       Impact factor: 47.728

4.  Incorporation of uracil into minus strand DNA affects the specificity of plus strand synthesis initiation during lentiviral reverse transcription.

Authors:  George J Klarmann; Xin Chen; Thomas W North; Bradley D Preston
Journal:  J Biol Chem       Date:  2002-11-27       Impact factor: 5.157

5.  The interaction of vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 In vivo mutation rate.

Authors:  L M Mansky; S Preveral; L Selig; R Benarous; S Benichou
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

6.  Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.

Authors:  Ann M Sheehy; Nathan C Gaddis; Jonathan D Choi; Michael H Malim
Journal:  Nature       Date:  2002-07-14       Impact factor: 49.962

7.  Altering the pathway of immunoglobulin hypermutation by inhibiting uracil-DNA glycosylase.

Authors:  Javier Di Noia; Michael S Neuberger
Journal:  Nature       Date:  2002-07-31       Impact factor: 49.962

8.  Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection.

Authors:  Sandra Kao; Hirofumi Akari; Mohammad A Khan; Markus Dettenhofer; Xiao-Fang Yu; Klaus Strebel
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 nucleocapsid zn(2+) fingers are required for efficient reverse transcription, initial integration processes, and protection of newly synthesized viral DNA.

Authors:  James S Buckman; William J Bosche; Robert J Gorelick
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

10.  The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.

Authors:  Hui Zhang; Bin Yang; Roger J Pomerantz; Chune Zhang; Shyamala C Arunachalam; Ling Gao
Journal:  Nature       Date:  2003-05-28       Impact factor: 49.962

View more
  184 in total

Review 1.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

2.  Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity.

Authors:  Xiaojun Wang; Aierken Abudu; Sungmo Son; Ying Dang; Patrick J Venta; Yong-Hui Zheng
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

3.  APOBEC3 proteins and genomic stability: the high cost of a good defense.

Authors:  Iñigo Narvaiza; Sébastien Landry; Matthew D Weitzman
Journal:  Cell Cycle       Date:  2012-01-01       Impact factor: 4.534

4.  APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis.

Authors:  Holly A Sadler; Mark D Stenglein; Reuben S Harris; Louis M Mansky
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

Review 5.  Role of HIV-1 nucleocapsid protein in HIV-1 reverse transcription.

Authors:  Judith G Levin; Mithun Mitra; Anjali Mascarenhas; Karin Musier-Forsyth
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

6.  The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its function during viral replication.

Authors:  Xiaoxia Wang; Zhujun Ao; Liyu Chen; Gary Kobinger; Jinyu Peng; Xiaojian Yao
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

7.  APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.

Authors:  Chawaree Chaipan; Jessica L Smith; Wei-Shau Hu; Vinay K Pathak
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

8.  Functional analysis and structural modeling of human APOBEC3G reveal the role of evolutionarily conserved elements in the inhibition of human immunodeficiency virus type 1 infection and Alu transposition.

Authors:  Yannick Bulliard; Priscilla Turelli; Ute F Röhrig; Vincent Zoete; Bastien Mangeat; Olivier Michielin; Didier Trono
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

9.  Hypermutation of an ancient human retrovirus by APOBEC3G.

Authors:  Young Nam Lee; Michael H Malim; Paul D Bieniasz
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

10.  Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences.

Authors:  Andrew E Armitage; Aris Katzourakis; Tulio de Oliveira; John J Welch; Robert Belshaw; Kate N Bishop; Beatrice Kramer; Andrew J McMichael; Andrew Rambaut; Astrid K N Iversen
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.